International Journal of Colorectal Disease

, Volume 34, Issue 10, pp 1795–1799 | Cite as

Treatment of complex recurrent fistula-in-ano by surgery combined to autologous bone marrow–derived mesenchymal stroma cells and platelet-rich plasma injection

  • Imed Ben Amor
  • Panagiotis LainasEmail author
  • Radwan Kassir
  • Hichem Chenaitia
  • Ibrahim Dagher
  • Jean Gugenheim
Case Report



We report a case of successful management of complex recurrent cryptoglandular fistula-in-ano by surgery combined with autologous bone marrow–derived mesenchymal stroma cells (MSCs) and platelet-rich plasma (PRP) injection.


Clinical, radiological, and surgical data of the patient were reviewed, as well as the current literature on complex fistula-in-ano.


A 37-year-old man with a recurrent cryptoglandular perianal fistula was addressed to our department. Inflammatory bowel disease was excluded by clinical history, endoscopy, and blood tests. Physical examination and MRI showed an anterior external orifice on the midline, 5 cm from the anal verge, with an internal orifice on the same line. Surgery combined to injection of MSC-PRP solution was successfully performed. MSC-PRP solution was prepared while the patient was under general anesthesia: bone marrow MSCs were obtained by centrifugation of a tibial puncture specimen and PRP from a peripheral whole blood sample of the patient. There were no adverse events post-operatively. Clinical and MRI examination 4 months after treatment confirmed the absence of perianal fistula. More than 2 years after surgery, there has been no recurrence.


Treatment of complex recurrent cryptoglandular fistula-in-ano by surgery combined to autologous bone marrow–derived MSCs and PRP injection seems safe in selected patients, allowing long-term healing. This procedure seems promising but further evaluation by clinical trials is warranted.


Fistula-in-ano Perianal fistula Mesenchymal stroma cells Platelet-rich plasma 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Zanotti C, Martinez-Puente C, Pascual I, Pascual M, Herreros D, Garcia-Olmo D (2007) An assessment of the incidence of fistula-in-ano in four countries of the European Union. Int J Color Dis 22:1459–1462CrossRefGoogle Scholar
  2. 2.
    Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L (2013) Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol 11:975–981 e971-974CrossRefGoogle Scholar
  3. 3.
    Molendijk I, Nuij VJ, van der Meulen-de Jong AE, van der Woude CJ (2014) Disappointing durable remission rates in complex Crohn’s disease fistula. Inflamm Bowel Dis 20:2022–2028CrossRefPubMedGoogle Scholar
  4. 4.
    Whiteford MH, Kilkenny J 3rd, Hyman N, Buie WD, Cohen J, Orsay C, Dunn G, Perry WB, Ellis CN, Rakinic J, Gregorcyk S, Shellito P, Nelson R, Tjandra JJ, Newstead G, Standards Practice Task F, American Society of C, Rectal S (2005) Practice parameters for the treatment of perianal abscess and fistula-in-ano (revised). Dis Colon Rectum 48:1337–1342CrossRefPubMedGoogle Scholar
  5. 5.
    Ford AC, Peyrin-Biroulet L (2013) Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 108:1268–1276CrossRefPubMedGoogle Scholar
  6. 6.
    Ciccocioppo R, Klersy C, Leffler DA, Rogers R, Bennett D, Corazza GR (2019) Systematic review with meta-analysis: safety and efficacy of local injections of mesenchymal stem cells in perianal fistulas. JGH Open 3:249–260CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ben-Ami E, Berrih-Aknin S, Miller A (2011) Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev 10:410–415CrossRefPubMedGoogle Scholar
  8. 8.
    Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41–49CrossRefPubMedGoogle Scholar
  9. 9.
    Sordi V (2009) Mesenchymal stem cell homing capacity. Transplantation 87:S42–S45CrossRefPubMedGoogle Scholar
  10. 10.
    Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le Blanc K (2007) No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92:1208–1215CrossRefPubMedGoogle Scholar
  11. 11.
    Georgiev-Hristov T, Guadalajara H, Herreros MD, Lightner AL, Dozois EJ, Garcia-Arranz M, Garcia-Olmo D (2018) A step-by-step surgical protocol for the treatment of perianal fistula with adipose-derived mesenchymal stem cells. J Gastrointest Surg 22:2003–2012CrossRefPubMedGoogle Scholar
  12. 12.
    Tsai HC, Lehman CW, Chen CM (2019) Use of platelet-rich plasma and platelet-derived patches to treat chronic wounds. J Wound Care 28:15–21CrossRefPubMedGoogle Scholar
  13. 13.
    Nauta AJ, Fibbe WE (2007) Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499–3506CrossRefPubMedGoogle Scholar
  14. 14.
    Lightner AL, Wang Z, Zubair AC, Dozois EJ (2018) A systematic review and meta-analysis of mesenchymal stem cell injections for the treatment of perianal Crohn’s disease: progress made and future directions. Dis Colon Rectum 61:629–640CrossRefGoogle Scholar
  15. 15.
    Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, Minelli A, Alvisi C, Vanoli A, Calliada F, Dionigi P, Perotti C, Locatelli F, Corazza GR (2011) Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 60:788–798CrossRefPubMedGoogle Scholar
  16. 16.
    de la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A (2013) Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Color Dis 28:313–323CrossRefGoogle Scholar
  17. 17.
    Barnhoorn MC, Van Halteren AGS, Van Pel M, Molendijk I, Struijk AC, Jansen PM, Verspaget HW, Dijkstra G, Oosten LEM, Van der Meulen-de Jong AE (2019) Lymphoproliferative disease in the rectum 4 years after local mesenchymal stromal cell therapy for refractory perianal Crohn’s fistulas: a case report. J Crohns Colitis 13:807–811CrossRefPubMedGoogle Scholar
  18. 18.
    Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S, Collaborators ACSG (2016) Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388:1281–1290CrossRefGoogle Scholar
  19. 19.
    Bouchard D, Pigot F, Staumont G, Siproudhis L, Abramowitz L, Benfredj P, Brochard C, Fathallah N, Faucheron JL, Higuero T, Panis Y, de Parades V, Vinson-Bonnet B, Laharie D (2018) Management of anoperineal lesions in Crohn’s disease: a French National Society of Coloproctology national consensus. Tech Coloproctol 22:905–917CrossRefPubMedGoogle Scholar
  20. 20.
    Herreros MD, Garcia-Arranz M, Guadalajara H, De-La-Quintana P, Garcia-Olmo D, Group FC (2012) Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula advanced therapy trial 1) and long-term evaluation. Dis Colon Rectum 55:762–772CrossRefPubMedGoogle Scholar
  21. 21.
    El-Sayed M, El-Feky MA, El-Amir MI, Hasan AS, Tag-Adeen M, Urata Y, Goto S, Luo L, Yan C, Li TS (2019) Immunomodulatory effect of mesenchymal stem cells: cell origin and cell quality variations. Mol Biol Rep 46:1157–1165CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Imed Ben Amor
    • 1
    • 2
    • 3
  • Panagiotis Lainas
    • 4
    • 5
    Email author
  • Radwan Kassir
    • 6
  • Hichem Chenaitia
    • 7
  • Ibrahim Dagher
    • 4
    • 5
  • Jean Gugenheim
    • 1
    • 2
    • 3
  1. 1.Department of Digestive SurgeryArchet II HospitalNiceFrance
  2. 2.University of Nice-Sophia-AntipolisNiceFrance
  3. 3.INSERM U1081NiceFrance
  4. 4.Department of Minimally Invasive Digestive SurgeryAntoine-Beclere Hospital, AP-HPClamartFrance
  5. 5.Paris-Saclay UniversityOrsayFrance
  6. 6.Department of Digestive SurgeryCHU Felix GuyonSaint-Denis La ReunionFrance
  7. 7.Clinique CitalNiceFrance

Personalised recommendations